GSK to Appeal Ruling

GlaxoSmithKline PLC
1 March 2002


Issued - Friday 1 March 2002, London


         Federal Court Rules in Wellbutrin SR / Zyban Patent Challenge


                              GSK to Appeal Ruling



GlaxoSmithKline (NYSE:GSK) today announced that a federal judge in the United
States has ruled on motions for summary judgement filed by GlaxoSmithKline and
Andrx Corporation (Andrx) relating to the infringement of one of GSK's patents
in the United States covering its products for the treatment of depression,
Wellbutrin SR, and its smoking cessation product, Zyban. The motions were filed
in connection with litigation commenced by GSK.

In the summary judgement ruling, the court ruled in Andrx's favour, saying that
GSK's patent expiring in 2013 was not infringed. Andrx has stated that it has
filed an abbreviated new drug application (ANDA) for the two products and is
awaiting approval.

GSK is actively reviewing the judge's ruling and intends to appeal immediately.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.


S M Bicknell

Company Secretary


Enquiries:
UK Media enquiries:                   Martin Sutton            [phone]
                                      Philip Thomson           [phone]
                                      Alan Chandler            [phone]

US Media enquiries:                   Nancy Pekarek            [phone]
                                      Mary Anne Rhyne          [phone]

European Analyst/Investor enquiries:  Duncan Learmouth         [phone]
                                      Anita Kidgell            [phone]

US Analyst/ Investor enquiries:       Frank Murdolo            [phone]
                                      Tom Curry                [phone]



                      This information is provided by RNS
            The company news service from the London Stock Exchange